Key Takeaways:
-
Janssen has hit pause on mots of its infectious disease programs amidst a strategic change.
Janssen Pharmaceuticals Inc. has hit the brakes on the development of partner Cidara Therapeutics, Inc.’s drug-Fc conjugate (DFC), CD388, for the prevention of influenza, but analysts believe the asset’s future remains promising.
The discontinuation is part of Janssen’s shift away from infectious diseases R&D amid a broader restructuring of its business and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?